DE102007009494A1 - Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung - Google Patents
Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung Download PDFInfo
- Publication number
- DE102007009494A1 DE102007009494A1 DE102007009494A DE102007009494A DE102007009494A1 DE 102007009494 A1 DE102007009494 A1 DE 102007009494A1 DE 102007009494 A DE102007009494 A DE 102007009494A DE 102007009494 A DE102007009494 A DE 102007009494A DE 102007009494 A1 DE102007009494 A1 DE 102007009494A1
- Authority
- DE
- Germany
- Prior art keywords
- formula
- alkyl
- compound
- compounds
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NHMWMEDLYXYIOV-UHFFFAOYSA-N CCOc1nccc2c1C(c(ccc(C#N)c1)c1OC(F)(F)F)C(C(N)=O)=C(C)N2 Chemical compound CCOc1nccc2c1C(c(ccc(C#N)c1)c1OC(F)(F)F)C(C(N)=O)=C(C)N2 NHMWMEDLYXYIOV-UHFFFAOYSA-N 0.000 description 1
- HLYLGLXFFLVKHN-UHFFFAOYSA-N CCOc1nccc2c1C(c(ccc(C#N)c1)c1OC(F)(F)F)C(C(OCCC#N)=O)=C(C)N2 Chemical compound CCOc1nccc2c1C(c(ccc(C#N)c1)c1OC(F)(F)F)C(C(OCCC#N)=O)=C(C)N2 HLYLGLXFFLVKHN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
Priority Applications (54)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007009494A DE102007009494A1 (de) | 2007-02-27 | 2007-02-27 | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
SA8290071A SA08290071B1 (ar) | 2007-02-27 | 2008-02-17 | مُركبات 4- أريل-4،1– ثنائي هيدرو-6،1- نافثيريدين أميدات مُستبدلة واستعمالها |
PA20088770101A PA8770101A1 (es) | 2007-02-27 | 2008-02-18 | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso |
UAA200909818A UA102065C2 (en) | 2007-02-27 | 2008-02-19 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
CA2679232A CA2679232C (en) | 2007-02-27 | 2008-02-19 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
PT87158499T PT2132206E (pt) | 2007-02-27 | 2008-02-19 | 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e a sua utilização |
UY30931A UY30931A1 (es) | 2007-02-27 | 2008-02-19 | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso |
KR1020097017818A KR101614164B1 (ko) | 2007-02-27 | 2008-02-19 | 치환된 4-아릴-1,4-디히드로-1,6-나프티리딘아미드 및 그의 용도 |
NZ579230A NZ579230A (en) | 2007-02-27 | 2008-02-19 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
JP2009550238A JP5367586B2 (ja) | 2007-02-27 | 2008-02-19 | 置換4−アリール−1,4−ジヒドロ−1,6−ナフチリジンアミドおよびそれらの使用 |
UY0001038952A UY38952A (es) | 2007-02-27 | 2008-02-19 | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y composiciones farmacéu-ticas que las contienen |
MX2009008701A MX2009008701A (es) | 2007-02-27 | 2008-02-19 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso. |
HUE08715849A HUE026441T2 (en) | 2007-02-27 | 2008-02-19 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and their use |
ES08715849.9T ES2540803T3 (es) | 2007-02-27 | 2008-02-19 | 4-Aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso |
CN2008800063770A CN101641352B (zh) | 2007-02-27 | 2008-02-19 | 取代的4-芳基-1,4-二氢-1,6-萘啶酰胺和其用途 |
BR122020008544A BR122020008544B8 (pt) | 2007-02-27 | 2008-02-19 | uso de 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, e medicamento |
AU2008221071A AU2008221071B2 (en) | 2007-02-27 | 2008-02-19 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
PCT/EP2008/001257 WO2008104306A2 (de) | 2007-02-27 | 2008-02-19 | Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung |
CL200800502A CL2008000502A1 (es) | 2007-02-27 | 2008-02-19 | Compuestos derivados de amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas; procedimiento de preparacion; medicamento; y uso del compuesto para el tratamiento y/o profilaxis de aldosteronismo, presion sanguinea alta, fallo cardiaco cronico, sec |
PE2008000351A PE20090724A1 (es) | 2007-02-27 | 2008-02-19 | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso |
BRPI0808098A BRPI0808098B8 (pt) | 2007-02-27 | 2008-02-19 | 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, seu uso e seu processo de preparação, e medicamento |
US12/526,951 US8436180B2 (en) | 2007-02-27 | 2008-02-19 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
MYPI20093470 MY150748A (en) | 2007-02-27 | 2008-02-19 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and their use |
RU2009135659A RU2470932C3 (ru) | 2008-02-19 | Замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение | |
SI200831451T SI2132206T1 (sl) | 2007-02-27 | 2008-02-19 | Substituirani 4-aril-1, 4-dihidro-1,6-nafthiridinamidi in njihova uporaba |
DK08715849.9T DK2132206T3 (en) | 2007-02-27 | 2008-02-19 | Substituted-4-aryl-1,4-dihydro-1,6-NAPHTHYRIDINAMIDER PRESENTATION |
MYPI2013000708A MY176873A (en) | 2007-02-27 | 2008-02-19 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use |
UY0001038953A UY38953A (es) | 2007-02-27 | 2008-02-19 | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y composiciones farmacéu-ticas que las contienen |
EP08715849.9A EP2132206B1 (de) | 2007-02-27 | 2008-02-19 | Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung |
PL08715849T PL2132206T3 (pl) | 2007-02-27 | 2008-02-19 | Podstawione 4-arylo-1,4-dihydro-1,6-naftyrydynamidy i ich zastosowanie |
ARP080100769A AR065463A1 (es) | 2007-02-27 | 2008-02-25 | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas, su uso en la fabricacion de un medicamento para el tratamiento de enfermedades cardiovasculares y un metodo para su preparacion. |
TW097106529A TWI415608B (zh) | 2007-02-27 | 2008-02-26 | 經取代之4-芳基-1,4-二氫-1,6-啶醯胺及其用途 |
TW102122083A TWI474821B (zh) | 2007-02-27 | 2008-02-26 | 經取代之4-芳基-1,4-二氫-1,6-啶醯胺及其用途 |
JOP/2008/0080A JO3018B1 (ar) | 2007-02-27 | 2008-02-26 | مُركبات 4- أريل- 1 , 4 – ثنائي هيدرو -1 , 6- نافثيريدين أميد amides مُستبدلة وإستعمالها |
IL200060A IL200060A (en) | 2007-02-27 | 2009-07-23 | 4-aryl-1,4-dihydro-1,6-naphthyridinamides are conserved and used |
TNP2009000318A TN2009000318A1 (en) | 2007-02-27 | 2009-07-30 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
GT200900230A GT200900230A (es) | 2007-02-27 | 2009-08-13 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso |
EC2009009581A ECSP099581A (es) | 2007-02-27 | 2009-08-14 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso |
DO2009000205A DOP2009000205A (es) | 2007-02-27 | 2009-08-14 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso |
HN2009001597A HN2009001597A (es) | 2007-02-27 | 2009-08-14 | 4-aril-1, 4-dihidro-1,6-naftiridinamidas sustituidas y su uso |
CUP2009000148A CU23874B1 (es) | 2007-02-27 | 2009-08-14 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso |
CR10976A CR10976A (es) | 2007-02-27 | 2009-08-14 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso |
ZA200905730A ZA200905730B (en) | 2007-02-27 | 2009-08-18 | Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides and use thereof |
CO09085903A CO6220951A2 (es) | 2007-02-27 | 2009-08-18 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso |
MA32211A MA31245B1 (fr) | 2007-02-27 | 2009-09-10 | Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci |
HK10106307.3A HK1140194A1 (en) | 2007-02-27 | 2010-06-28 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof 4--14--16- |
US13/801,376 US9051316B2 (en) | 2007-02-27 | 2013-03-13 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use |
JP2013162179A JP5752754B2 (ja) | 2007-02-27 | 2013-08-05 | 置換4−アリール−1,4−ジヒドロ−1,6−ナフチリジンアミドおよびそれらの使用 |
HRP20150702TT HRP20150702T1 (hr) | 2007-02-27 | 2015-06-30 | Supstituirani 4-aril-1,4-dihidro-1,6-naftiridinamidi i njihova uporaba |
CY20151100566T CY1116455T1 (el) | 2007-02-27 | 2015-06-30 | Υποκατεστημενα 4-αρυλο-1,4-διυδρο-1,6-ναφθυριδιν αμιδια και η χρηση τους |
HUS2200015C HUS2200015I1 (hu) | 2007-02-27 | 2022-05-03 | Szubsztituált 4-aril-1,4-dihidro-1,6-naftiridinamidok és alkalmazásuk |
FR22C1017C FR22C1017I2 (fr) | 2007-02-27 | 2022-05-05 | Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitues et utilisation de ceux-ci |
LTPA2022512C LTPA2022512I1 (pt-PT) | 2007-02-27 | 2022-06-21 | |
NL301192C NL301192I2 (nl) | 2007-02-27 | 2022-08-11 | Finerenon en zijn zouten, solvaten en solvaten van de zouten daarvan |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007009494A DE102007009494A1 (de) | 2007-02-27 | 2007-02-27 | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
DE102007009494A1 true DE102007009494A1 (de) | 2008-08-28 |
Family
ID=39512753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE102007009494A Withdrawn DE102007009494A1 (de) | 2007-02-27 | 2007-02-27 | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
Country Status (45)
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103193704A (zh) * | 2013-04-12 | 2013-07-10 | 四川铂瑞生物医药有限公司 | 2-羟基-4-氨基-5-甲基吡啶杂环化合物 |
WO2016001631A1 (en) | 2014-06-30 | 2016-01-07 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
DE102017008472A1 (de) | 2017-09-08 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten |
WO2018153898A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
MX363161B (es) | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica. |
US10156567B2 (en) | 2012-12-17 | 2018-12-18 | General Electric Company | In-vitro magnetic resonance detection of a target substance without separating bound magnetic nanoparticles from unbound magnetic nanoparticles |
KR20230152818A (ko) | 2013-03-15 | 2023-11-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
CA2907214A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
PL3174875T3 (pl) | 2014-08-01 | 2021-01-25 | Bayer Pharma Aktiengesellschaft | Sposób wytwarzania (4S)-4-(4-cyjano-2-metoksyfenylo)-5-etoksy-2,8-dimetylo-1,4-dihydro-1,6-naftyrydyno-3-karboksyamidu i jego oczyszczanie do zastosowania jako aktywny składnik farmaceutyczny |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
RU2715226C2 (ru) * | 2015-08-21 | 2020-02-26 | Байер Фарма Акциенгезельшафт | Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида и выделения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида посредством электрохимических методов |
USRE49826E1 (en) * | 2015-08-21 | 2024-02-06 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
CN108473488A (zh) * | 2015-08-21 | 2018-08-31 | 拜耳制药股份公司 | (4s)-和(4r)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-甲酰胺的代谢物的制备方法及其用途 |
JP6835836B2 (ja) | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
UY36999A (es) | 2015-12-02 | 2017-06-30 | Syngenta Participations Ag | Derivados de aryl oxadiazol fungicidas |
EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
US11447481B2 (en) | 2017-06-02 | 2022-09-20 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
CN109721536B (zh) * | 2017-10-27 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基取代的稠合三环类化合物及其用途 |
EP3560922A1 (de) | 2018-04-24 | 2019-10-30 | Bayer Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester |
AU2019272300A1 (en) * | 2018-05-22 | 2020-12-03 | Sunshine Lake Pharma Co., Ltd. | Phenyl-substituted dihydronaphthyridine compound and use thereof |
CN110917195A (zh) * | 2018-08-20 | 2020-03-27 | 山西惠尔健生物科技有限公司 | 肌松剂阿库氯铵(Alcuronium chloride)可作为抗心律失常药物 |
BR112021015799A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado |
PE20220251A1 (es) | 2019-03-05 | 2022-02-16 | Bayer Ag | Procedimiento para la preparacion de 4-amino-5-metilpiridona |
PE20212199A1 (es) | 2019-03-05 | 2021-11-16 | Bayer Ag | Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermedio para la sintesis del antagonista finerenona de mr) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermedio 2-cloro-5-metil-4-piridinamina |
AU2020365351A1 (en) * | 2019-10-17 | 2022-05-12 | Bayer Aktiengesellschaft | Photochemical process for producing (4R,4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide |
EP4045499A1 (de) * | 2019-10-17 | 2022-08-24 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester |
AU2020365314A1 (en) * | 2019-10-17 | 2022-05-12 | Bayer Aktiengesellschaft | Process for producing acyloxymethyl esters of (4S)-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylic acid |
IL292180A (en) * | 2019-10-17 | 2022-06-01 | Bayer Ag | A process for the preparation of 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-8,2-dimethyl-4,1-dihydro-6,1-naphthyridine-3-carboxylate on by resolution of racemates using diastereomeric tartaric acid esters |
WO2021180818A1 (en) | 2020-03-11 | 2021-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
EP3900722A1 (en) | 2020-04-22 | 2021-10-27 | Bayer AG | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
CN115916197A (zh) | 2020-04-22 | 2023-04-04 | 拜耳公司 | 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合 |
CN113549066B (zh) * | 2020-04-24 | 2023-07-21 | 年衍药业(珠海)有限公司 | 二氢萘啶类化合物的晶型及其用途 |
CN113549067B (zh) * | 2020-04-24 | 2023-10-03 | 年衍药业(珠海)有限公司 | 二氢萘啶类化合物的晶型及其用途 |
WO2021254896A1 (en) | 2020-06-16 | 2021-12-23 | Bayer Aktiengesellschaft | Process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide enabled by a catalytic asymmetric hantzsch ester reduction |
WO2022214206A1 (en) | 2021-04-08 | 2022-10-13 | Bayer Aktiengesellschaft | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2023004002A1 (en) * | 2021-07-21 | 2023-01-26 | Cyta Therapeutics, Inc. | Particle delivery of thyroid hormone receptor agonists and antagonists |
EP4395785A1 (en) | 2021-08-31 | 2024-07-10 | Inserm (Institut National de la Santé et de la Recherche Scientifique) | Methods for the treatment of ocular rosacea |
KR20240068057A (ko) | 2021-09-18 | 2024-05-17 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 치환된 1,4-다이하이드로-1,6-나프티리딘 아미드 및 이의 용도 |
CN114149427A (zh) * | 2021-12-18 | 2022-03-08 | 上海鼎雅药物化学科技有限公司 | 非奈利酮及其中间体的合成方法 |
WO2023205164A1 (en) | 2022-04-18 | 2023-10-26 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of finerenone |
EP4286368A1 (de) | 2022-05-31 | 2023-12-06 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril |
WO2024022481A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏中药业集团股份有限公司 | 苯基取代的二氢萘啶类化合物及其制备与用途 |
WO2024110523A1 (en) | 2022-11-23 | 2024-05-30 | Bayer Aktiengesellschaft | Treatment of chronic kidney disease in type i diabetes mellitus |
WO2024126694A1 (en) | 2022-12-16 | 2024-06-20 | Bayer Aktiengesellschaft | Sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
CN116715664A (zh) * | 2023-06-12 | 2023-09-08 | 常州制药厂有限公司 | 一种非奈利酮关键中间体的制备方法 |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0133530A2 (de) | 1983-07-30 | 1985-02-27 | Gödecke Aktiengesellschaft | 1,6-Naphthyridinon-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
EP0173933A1 (de) | 1984-08-25 | 1986-03-12 | Gödecke Aktiengesellschaft | 1,6-Naphthyridin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
EP0189898A1 (de) | 1985-01-29 | 1986-08-06 | Gödecke Aktiengesellschaft | 1,6-Naphthyridinon-Derivate und Verfahren zu deren Herstellung |
EP0234516A1 (de) | 1984-08-25 | 1987-09-02 | Gödecke Aktiengesellschaft | 1,6-Naphthyridin-Derivate,Verfahren zu deren Herstellung und diese enthaltende Arzneimittel zur Behandlung von Gefässerkrankungen |
WO2000006568A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Substituierte pyrazolderivate |
WO2000006569A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate |
WO2001019780A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2001019355A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Dicarbonsäurederivate mit neuartigen pharmazeutischen eigenschaften |
WO2001019778A1 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2001019776A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2002010164A2 (en) | 2000-08-02 | 2002-02-07 | Abbott Laboratories | Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers |
WO2002042301A1 (de) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Neue pyridin-substituierte pyrazolopyridinderivate |
WO2002070510A2 (de) | 2001-03-07 | 2002-09-12 | Bayer Aktiengesellschaft | Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2002070462A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Aktiengesellschaft | Substituierte aminodicarbonsäurederivate |
WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
WO2005087740A1 (de) | 2004-03-13 | 2005-09-22 | Bayer Healthcare Ag | Fluorenone 1, 4,-dihydrpyridinderivate |
WO2005097118A1 (ja) | 2004-04-05 | 2005-10-20 | Takeda Pharmaceutical Company Limited | アルドステロン受容体拮抗剤 |
WO2006066011A2 (en) | 2004-12-13 | 2006-06-22 | Irm Llc | Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
WO2007009670A1 (de) | 2005-07-22 | 2007-01-25 | Bayer Healthcare Ag | 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
US4760081A (en) | 1984-08-25 | 1988-07-26 | Goedecke Aktiengesellschaft | 1,6-naphthyridine derivatives useful for treating diseases of the blood vessels |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
DE602006020138D1 (de) | 2005-06-29 | 2011-03-31 | Compumedics Ltd | Sensoranordnung mit leitfähiger brücke |
DE102006026585A1 (de) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung |
DE102006026583A1 (de) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
-
2007
- 2007-02-27 DE DE102007009494A patent/DE102007009494A1/de not_active Withdrawn
-
2008
- 2008-02-17 SA SA8290071A patent/SA08290071B1/ar unknown
- 2008-02-18 PA PA20088770101A patent/PA8770101A1/es unknown
- 2008-02-19 CN CN2008800063770A patent/CN101641352B/zh active Active
- 2008-02-19 PE PE2008000351A patent/PE20090724A1/es active IP Right Grant
- 2008-02-19 CL CL200800502A patent/CL2008000502A1/es unknown
- 2008-02-19 PL PL08715849T patent/PL2132206T3/pl unknown
- 2008-02-19 AU AU2008221071A patent/AU2008221071B2/en active Active
- 2008-02-19 PT PT87158499T patent/PT2132206E/pt unknown
- 2008-02-19 BR BR122020008544A patent/BR122020008544B8/pt active IP Right Grant
- 2008-02-19 WO PCT/EP2008/001257 patent/WO2008104306A2/de active Application Filing
- 2008-02-19 UY UY30931A patent/UY30931A1/es active IP Right Grant
- 2008-02-19 ES ES08715849.9T patent/ES2540803T3/es active Active
- 2008-02-19 JP JP2009550238A patent/JP5367586B2/ja active Active
- 2008-02-19 EP EP08715849.9A patent/EP2132206B1/de active Active
- 2008-02-19 MX MX2009008701A patent/MX2009008701A/es active IP Right Grant
- 2008-02-19 UY UY0001038952A patent/UY38952A/es not_active Application Discontinuation
- 2008-02-19 UA UAA200909818A patent/UA102065C2/ru unknown
- 2008-02-19 MY MYPI20093470 patent/MY150748A/en unknown
- 2008-02-19 UY UY0001038953A patent/UY38953A/es not_active Application Discontinuation
- 2008-02-19 MY MYPI2013000708A patent/MY176873A/en unknown
- 2008-02-19 KR KR1020097017818A patent/KR101614164B1/ko active IP Right Grant
- 2008-02-19 CA CA2679232A patent/CA2679232C/en active Active
- 2008-02-19 BR BRPI0808098A patent/BRPI0808098B8/pt active IP Right Grant
- 2008-02-19 DK DK08715849.9T patent/DK2132206T3/en active
- 2008-02-19 HU HUE08715849A patent/HUE026441T2/en unknown
- 2008-02-19 US US12/526,951 patent/US8436180B2/en active Active
- 2008-02-19 NZ NZ579230A patent/NZ579230A/en unknown
- 2008-02-19 SI SI200831451T patent/SI2132206T1/sl unknown
- 2008-02-25 AR ARP080100769A patent/AR065463A1/es active IP Right Grant
- 2008-02-26 TW TW102122083A patent/TWI474821B/zh active
- 2008-02-26 JO JOP/2008/0080A patent/JO3018B1/ar active
- 2008-02-26 TW TW097106529A patent/TWI415608B/zh active
-
2009
- 2009-07-23 IL IL200060A patent/IL200060A/en active IP Right Grant
- 2009-07-30 TN TNP2009000318A patent/TN2009000318A1/fr unknown
- 2009-08-13 GT GT200900230A patent/GT200900230A/es unknown
- 2009-08-14 CU CUP2009000148A patent/CU23874B1/es active IP Right Grant
- 2009-08-14 HN HN2009001597A patent/HN2009001597A/es unknown
- 2009-08-14 CR CR10976A patent/CR10976A/es unknown
- 2009-08-14 DO DO2009000205A patent/DOP2009000205A/es unknown
- 2009-08-14 EC EC2009009581A patent/ECSP099581A/es unknown
- 2009-08-18 ZA ZA200905730A patent/ZA200905730B/xx unknown
- 2009-08-18 CO CO09085903A patent/CO6220951A2/es not_active Application Discontinuation
- 2009-09-10 MA MA32211A patent/MA31245B1/fr unknown
-
2010
- 2010-06-28 HK HK10106307.3A patent/HK1140194A1/xx unknown
-
2013
- 2013-03-13 US US13/801,376 patent/US9051316B2/en active Active
- 2013-08-05 JP JP2013162179A patent/JP5752754B2/ja active Active
-
2015
- 2015-06-30 HR HRP20150702TT patent/HRP20150702T1/hr unknown
- 2015-06-30 CY CY20151100566T patent/CY1116455T1/el unknown
-
2022
- 2022-05-03 HU HUS2200015C patent/HUS2200015I1/hu unknown
- 2022-05-05 FR FR22C1017C patent/FR22C1017I2/fr active Active
- 2022-06-21 LT LTPA2022512C patent/LTPA2022512I1/lt unknown
- 2022-08-11 NL NL301192C patent/NL301192I2/nl unknown
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0133530A2 (de) | 1983-07-30 | 1985-02-27 | Gödecke Aktiengesellschaft | 1,6-Naphthyridinon-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
EP0173933A1 (de) | 1984-08-25 | 1986-03-12 | Gödecke Aktiengesellschaft | 1,6-Naphthyridin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
EP0234516A1 (de) | 1984-08-25 | 1987-09-02 | Gödecke Aktiengesellschaft | 1,6-Naphthyridin-Derivate,Verfahren zu deren Herstellung und diese enthaltende Arzneimittel zur Behandlung von Gefässerkrankungen |
EP0189898A1 (de) | 1985-01-29 | 1986-08-06 | Gödecke Aktiengesellschaft | 1,6-Naphthyridinon-Derivate und Verfahren zu deren Herstellung |
WO2000006568A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Substituierte pyrazolderivate |
WO2000006569A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate |
WO2001019778A1 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2001019355A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Dicarbonsäurederivate mit neuartigen pharmazeutischen eigenschaften |
WO2001019780A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2001019776A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2002010164A2 (en) | 2000-08-02 | 2002-02-07 | Abbott Laboratories | Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers |
WO2002042301A1 (de) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Neue pyridin-substituierte pyrazolopyridinderivate |
WO2002070510A2 (de) | 2001-03-07 | 2002-09-12 | Bayer Aktiengesellschaft | Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2002070462A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Aktiengesellschaft | Substituierte aminodicarbonsäurederivate |
WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
WO2005087740A1 (de) | 2004-03-13 | 2005-09-22 | Bayer Healthcare Ag | Fluorenone 1, 4,-dihydrpyridinderivate |
WO2005097118A1 (ja) | 2004-04-05 | 2005-10-20 | Takeda Pharmaceutical Company Limited | アルドステロン受容体拮抗剤 |
WO2006066011A2 (en) | 2004-12-13 | 2006-06-22 | Irm Llc | Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
WO2007009670A1 (de) | 2005-07-22 | 2007-01-25 | Bayer Healthcare Ag | 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung |
Non-Patent Citations (28)
Title |
---|
B. Pitt, F. Zannad, W. J. Remme et al., N. Engl. J. Med. 341, 709-717 (1999) |
B. Pitt, W. Remme, F. Zannad et al., N. Engl. J. Med. 348, 1309-1321 (2003) |
Bisagni, E., Hung, N. C., Synthesis, 765-766 (1984) |
D. M. Stout, A. I. Meyers, Chem. Rev. 1982, 82, 223-243 |
D. McNamara, P. D. Cook, J. Med. Chem. 30, 340-347 (1987) |
Ehlert, F. J., Roeske, W. R., Itoga E., Yamamura, H. I., Life Sci. 30, 2191-2202 (1982) |
F. Bossert et al., Angew. Chem. 1981, 93, 755] |
G. W. Kenner et al., J. Chem. Soc., 388 (1943) |
G. Werner et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 344 (3), 337-344 (1991) |
Gould, R.J., Murphy, K. M. M., Snyder, S. H., Proc. Natl. Acad. Sci. U.S.A. 79, 3656-3660 |
H. A. Kühn und J. Schirmeister (Hrsg.), Innere Medizin, 4. Aufl., Springer Verlag, Berlin, 1982 |
H. Meier et al., ibid. 1976, 1762 |
H. Meier et al., ibid. 1977, 1895 |
H. Meier et al., Liebigs Ann. Chem. 1977, <?page 10?>1888 |
I. I. Barabanov et al., Russ. Chem. Bl. 47 (11), 2256-2261 (1998) |
M. A. Zaman, S. Oparil, D. A. Calhoun, Nature Rev. Drug Disc. 1, 621-636 (2002) |
Moseley, J. D., Tetrahedron Lett. 46, 3179-3 181 (2005) |
Moseley, J. D., Tetrahedron Lett. 46, 3179-3181 (2005) |
N. C. Hung, E. Bisagni, Synthesis 1984, 765-766 |
Prävalenz bis 11% aller Hypertoniker: L. Seiler und M. Reincke, Der Aldosteron-Renin-Quotient bei sekundärer Hypertonie, Herz 28, 686-691 (2003) |
R. E. Booth, J. P. Johnson, J. D. Stockand, Adv. Physiol. Educ. 26 (1), 8-20 (2002) |
R. Schwesinger, H. Schlemper, Angew. Chem. Int. Ed. Engl. 26, 1167 (1987) |
S. Nesnow, C. Heidelberger, J. Heterocycl. Chem. 12, 941-944 (1975) |
Searls, T., McLaughlin, L. W., Tetrahedron 55, 11985-11996 (1999) |
T. Pietzonka, D. Seebach, Chem. Ber. 124, 1837 (1991) |
T. Searls, L. W. McLaughlin, Tetrahedron 55, 11985-11996 (1999) |
Yamamoto, T., et al., Bioorg. Med. Chem. Lett. 16, 798-802 (2006) |
Z. Földi et al., Chem. Ber. 75 (7), 755-763 (1942) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103193704B (zh) * | 2013-04-12 | 2016-03-09 | 四川铂瑞生物医药有限公司 | 2-羟基-4-氨基-5-甲基吡啶杂环化合物 |
CN103193704A (zh) * | 2013-04-12 | 2013-07-10 | 四川铂瑞生物医药有限公司 | 2-羟基-4-氨基-5-甲基吡啶杂环化合物 |
US10017502B2 (en) | 2014-06-30 | 2018-07-10 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
WO2016001631A1 (en) | 2014-06-30 | 2016-01-07 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
US9394291B2 (en) | 2014-06-30 | 2016-07-19 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
CN109890379A (zh) * | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
CN110022871A (zh) * | 2016-10-11 | 2019-07-16 | 拜耳制药股份公司 | 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品 |
US10918639B2 (en) | 2016-10-11 | 2021-02-16 | Bayer Pharma Aktiengesellschaft | Combination containing SGC stimulators and mineralocorticoid receptor antagonists |
US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
US11684621B2 (en) | 2016-10-11 | 2023-06-27 | Bayer Pharma Aktiengesellschaft | Combination containing sGC stimulators and mineralocorticoid receptor antagonists |
WO2018153898A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
DE102017008472A1 (de) | 2017-09-08 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2132206B1 (de) | Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung | |
EP2035419B1 (de) | 5-aryl-substituierte dihydropyridopyrimidine und dihydropyridazine und ihre verwendung als mineralkorticoidanatgonisten | |
EP2029591B1 (de) | Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridine und ihre verwendung | |
DE102008030206A1 (de) | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung | |
EP2086969B1 (de) | 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihre verwendung zur behandlung kardiovaskulärer erkrankungen | |
DE102008039083A1 (de) | Substituierte 5-Aminopyrazole und ihre Verwendung | |
DE102008039082A1 (de) | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung | |
DE102008030207A1 (de) | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung | |
RU2470932C9 (ru) | Замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8127 | New person/name/address of the applicant |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE |
|
R081 | Change of applicant/patentee |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE Effective date: 20120612 |
|
R081 | Change of applicant/patentee |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE Effective date: 20130410 |
|
R005 | Application deemed withdrawn due to failure to request examination |
Effective date: 20140228 |